Great Lakes Advisors LLC acquired a new position in Harrow, Inc. (NASDAQ:HROW - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,963 shares of the company's stock, valued at approximately $972,000. Great Lakes Advisors LLC owned about 0.08% of Harrow as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of HROW. Principal Financial Group Inc. bought a new stake in shares of Harrow in the third quarter worth $329,000. Oppenheimer & Co. Inc. acquired a new position in Harrow in the third quarter valued at $1,267,000. Huntington National Bank acquired a new position in Harrow in the third quarter valued at $164,000. Quest Partners LLC acquired a new position in Harrow in the third quarter valued at $29,000. Finally, First Turn Management LLC acquired a new position in Harrow in the third quarter valued at $14,683,000. Institutional investors own 72.76% of the company's stock.
Wall Street Analysts Forecast Growth
HROW has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Harrow in a report on Tuesday. B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a report on Wednesday, December 4th.
Check Out Our Latest Stock Report on HROW
Harrow Stock Up 1.1 %
Shares of NASDAQ HROW traded up $0.30 during trading on Wednesday, hitting $27.28. 988,839 shares of the company traded hands, compared to its average volume of 504,623. The business's fifty day moving average is $30.01 and its 200 day moving average is $38.63. Harrow, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $59.23. The firm has a market capitalization of $971.58 million, a price-to-earnings ratio of -29.02 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
